Covid19
Conditions
Keywords
Covid19, Oral anticoagulant, VKA, DOAC, Antiplatelet therapy, Heparin, Low molecular-weight heparin
Brief summary
CORONA is a retrospective, observational, one center study to investigate the clinical evolution (in terms of survival and thromboembolic complications) of patients on chronic treatment with anticoagulants or antiplatelet agents who are admitted to the hospital for COVID-19 compared with patients who do not receive anticoagulants or antiplatelet agents.
Interventions
OTHERAntithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19
Review of medical records during hospitalization and until day 28 post-entry to compare the clinical outcomes depending on previous antithrombotic therapy
Sponsors
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patient admitted for COVID-19 at the Hospital de la Santa Creu i Sant Pau, * Positive COVID-19 polymerase chain reaction test * Length of stay more than 24 hours
Exclusion criteria
* No objective diagnose for COVID-19 * Outpatient * Lenght of stay less than 24hours
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transfer to the Intensive Care Unit (ICU) | From hospital admission to day 28 |
| Mortality | From hospital admission to day 28 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Thromboembolic complications | From hospital admission to day 28 | Venous thromboembolism, ischemic stroke, myocardial infarction or periferal arterial thrombosis during hospitalization for Covid19 |
| Major bleeding complications | From hospital admission to day 28 | Any bleeding complication grade 3 or 5 according BARC classification |
Countries
Spain
Outcome results
None listed